Advertisement

Sterically Stabilized Immunoliposomes: Formulations for Delivery of Drugs and Genes to Tumor Cells in Vivo

  • J. W. Park
  • D. Kirpotin
  • K. Hong
  • W. Zheng
  • Y. Shao
  • O. Meyer
  • C. C. Benz
  • D. Papahadjopoulos
Chapter
Part of the NATO ASI Series book series (NSSA, volume 300)

Abstract

Immunoliposomes represent a promising strategy to achieve targeted drug delivery for the treatment of cancers overexpressing specific surface receptors. Advances in immunoliposome design have been facilitated by independent progress in the areas of antibody-based therapeutics and liposomes, which can now be utilized for tumor-targeted drug delivery Park et al., 1997a).

Keywords

Cationic Liposome Intracellular Delivery Intracellular Drug Delivery Stabilize Liposome Liposomal Drug Delivery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, CA., Moore, J., Rosen, P.P., Twaddell, T., Henderson, I.C. and Norton, L., 1996, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer, J. Clin. One. 14:737.Google Scholar
  2. Baselga, J., Norton, L., Shalaby, R. and Mendelsohn, J., 1994, Anti-HER2 humanized monoclonal antibody (Mab) alone and in combination with chemotherapy against breast carcinoma xenografts, Proc. Amer. Soc. Clin. Oncol. 13:63.Google Scholar
  3. Gaber, M.H., Hong, K., Huang, S-K. and Papahadjopoulos, D., 1995, Thermosensitive sterically stabilized liposomes: Formulation and in vitro studies on mechanism of doxorubicin release, Pharmaceut Res. 2:1407.CrossRefGoogle Scholar
  4. Gaber, M.H., Wu, N., Hong, K., Huang, S., Dewhirst, M. and Papahadjopoulos, D., 1996, Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks, Intl J Rad Oncol Biol Phys. 36 1177.CrossRefGoogle Scholar
  5. Hong, K., Zheng, W., Baker, A. and Papahadjopoulos, D., 1997, Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery, FEBS Lett. 400:233.PubMedCrossRefGoogle Scholar
  6. Huang, S.K., Mayhew, E.M., Gilani, S., Lasic, D.D., Martin, F.J. and Papahadjopoulos, D., 1992a, Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma, Cancer Res. 52: 6774.PubMedGoogle Scholar
  7. Huang, S.K., Lee, K.D., Hong, K., Friend, D.S. and Papahadjopoulos, D., 1992b, Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice, Cancer Res. 52:5135.PubMedGoogle Scholar
  8. Hynes, N.E., and Stern, D.F., 1994, The biology of erbB-2/neu/HER-2 and its role in cancer, Biochim. Biophys. Acta. 1198:165.PubMedGoogle Scholar
  9. Kirpotin, D., Park, J.W., Hong, K., Zalipsky, S., LI, W.L., Carter, P., Benz, C.C. and Papahadjopoulos, D., 1997a, Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cell in vitro, Biochemistry. 36:66.PubMedCrossRefGoogle Scholar
  10. Kirpotin, D., Park, J.W., Hong, K., Shao, Y., Shalaby, R., Cobern, G., Benz, C. and Papahadjopoulos, D., 1997b, Targeting of liposomes to solid tumors: the case of sterically stabized anti-HER2 immunoliposomes, Forum on “Liposomes Targeting In Animal Models”, J Liposome Res. 7(4):391.CrossRefGoogle Scholar
  11. Kirpotin, D., Hong, K., Mullah, N., Papahadjopoulos, D., and Zalipsky, S., 1997c, Liposomes with detachable polymer coating: destabilization and fusion of dioleylphosphatidylethanolamine vesicles trigered by cleavage of surface grafted PEG, FEBS Lett. 388:115.CrossRefGoogle Scholar
  12. Lasic, D.D. and Martin, F.J., eds, 1995, Chapters 1, 19, 11, 12, 14, 21, 22, in: Stealth Liposomes. CRC, Boca Raton.Google Scholar
  13. Lewis, G.D., Figari, I., Fendly, B., Wong, W.L., Carter, P., Gorman, C., and Shepard, H.M., 1993, Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies, Cancer Immunol. Immunother. 37:255.PubMedCrossRefGoogle Scholar
  14. Meyer, O., Kirpotin, D., Hong, K., Sternberg, B., Park, J.W., Woodle, M.C., and Papahadjopoulos, D., 1998, Cationic liposomes coated with poly(ethylene glycol) as carriers for oligonucleotides, J Biol Chem. submitted.Google Scholar
  15. Muss, H.B., Thor, A.D., Berry, D.A., Kute, T., Liu, E.T., Koerner, F., Cirrincione, C.T., Budman, D.R., Wood, W.C., Barcos, M. and Henderson, I.C., 1994, c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer, N. Engl. J. Med. 330:1260.PubMedCrossRefGoogle Scholar
  16. O’Connell, R.P., Carter, P., Presta, L., Eigenbrot, C., Covarrubias, M., Snedecor, B., Speckart, R., Blank, G., Vetterlein, D. and Kotts, C, 1993, Characterization of humanized anti-p185HER2 antibody Fab fragments produced in E.coli. in: Protein Folding In Vivo and In Vitro, J. L. Cleland, ed., American Chemical Society, Washington, D.C.Google Scholar
  17. Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.D., Woodle, M.C., Lasic, D.D., Redemann, C. and Martin, F.J., 1991, Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl. Acad. Sci. USA. 88:11460.PubMedCrossRefGoogle Scholar
  18. Park, J.W., Hong, K., Kirpotin, D.B., Papahadjopoulos, D., and Benz, C.C., 1997a, Immunoliposomes for cancer treatment, in: Gene Therapy, J. T. August, M. W. Anders, F. Murad, and J. T. Coyle, eds, Academic Press, San Diego.Google Scholar
  19. Park, J.W., Hong, K., Carter, P., Asgari, H., Guo, L.Y., Keller, G.A., Wirth, C, Shalaby, R., Kotts, C, Wood, W.I., Papahadjopoulos, D. and Benz, C.C, 1995, Development of anti-p185HER2 immunoliposomes for cancer therapy, Proc. Natl. Acad. Sci. USA. 92:1327.PubMedCrossRefGoogle Scholar
  20. Park, J.W., Colbern, G., Baselga, J., Hong, K., Shao, Y., Kirpotin, D., Nuijens, A., Wood, W., Papahadjopoulos, D. and Benz, C, 1996, Antitumor efficacy of anti-p185HER2 immunoliposomes: enhanced therapeutic index due to targeted delivery, Proc. Amer. Soc. Clin. Oncol. 15:501.Google Scholar
  21. Park, J., Hong, K., Kirpotin, D., Meyer, O., Papahadjopoulos, D. and Benz, C., 1997b, Anti-HER2 immunoliposomes for targeted therapy of human tumors, Cancer Lett. 188:153.CrossRefGoogle Scholar
  22. Pegram, M., Lipton, A., Pietras, R., Hayes, D., Weber, B., Baselga, J., Tripathy, D., Twaddell, T., Glaspy, J. and Slamon, D., 1996, Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer, Proc. ASCO. 14:106.Google Scholar
  23. Press, M.F., Cordon-Cardo, C. and Slamon, D.J., 1990, Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues, Oncogene. 5:953.PubMedGoogle Scholar
  24. Rosenecker, J., Zhang, W., Hong, K., Lausier, J., Geppetti, P., Yoshihara, S., Papahadjopoulos, D. and Nadel, J., 1996, Increased liposome extravasation in selected tissues: effect of substance, P. Proc Natl Acad Sci USA. 93:7236.CrossRefGoogle Scholar
  25. Shepard, H.M., Lewis, G.D., Sarup, J.C., Fendly, B.M., Maneval, D., Mordenti, J., Figari, I., Kotts, C.E., Palladino, M.A., Ullrich, A. and Slamon, D., 1991, Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic, J. Clin. Immunol. 11:117.PubMedCrossRefGoogle Scholar
  26. Zhang, W., Guo, L., Nadel, J. and Papahadjopoulos D., 1998, Inhibition of tracheal veascular extravasation by liposome-encapsulated albuterol in rat, Pharm. Res. in press.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • J. W. Park
    • 2
  • D. Kirpotin
    • 1
    • 3
  • K. Hong
    • 1
    • 3
  • W. Zheng
    • 1
    • 3
  • Y. Shao
    • 1
    • 3
  • O. Meyer
    • 1
    • 3
  • C. C. Benz
    • 2
  • D. Papahadjopoulos
    • 1
    • 3
  1. 1.Department of Cellular and Molecular PharmacologyUCSFSan FranciscoUSA
  2. 2.Division of Hematology/Oncology, Cancer Research InstUCSFSan FranciscoUSA
  3. 3.Liposome Research LaboratoryCPMCRISan FranciscoUSA

Personalised recommendations